Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 48,563 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Neoplasms, Melanoma
Interventions: Modakafusp Alfa, Pembrolizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 12 more

Conditions: Osteoarthitis
Interventions: Cannabidiol (CBD), Castor Oil (Placebo); Dietary Supplement · Other
Lead sponsor: University of Tennessee; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Depression, Information Dissemination, Social Determinants of Health
Interventions: Quality Improvement Program, Resources for Services Expert Team, Community Engagement and Planning Council; Other · Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Gardena, California

Conditions: Opioid-Related Disorders
Interventions: Youth Opioid Recovery Support; Behavioral
Lead sponsor: Potomac Health Foundations; Other
Eligibility: 18 Years to 26 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mental Health Disorder, Substance Use Disorder, Stigmatization, Implementation Science
Interventions: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum, You℞ Decision prescribing platform; Behavioral · Device
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Decatur, Georgia • Duluth, Georgia

Conditions: Advance Care Planning, Dementia
Interventions: SHARING Choices; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 64,915 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 54
States / cities: Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 30 more

Conditions: Ileus
Interventions: Cycle Therapy; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Diabetic Macular Edema
Interventions: Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 100
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more

Conditions: High Grade Glioma, Glioblastoma
Interventions: Standard Surgical Treatment, Intraoperative Electrocorticography; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastrointestinal Dysmotility
Interventions: Endoscopic procedure; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Agitation
Interventions: acupuncture, sham acupuncture; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Months to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity or Overweight
Interventions: AZD6234, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Conditions: Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions: Copanlisib, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Chronic, Fatigue Syndrome, Chronic, Aging
Interventions: Otago, Gentle yogic breathing, Behavioral Activation, Caregiver Gentle yogic breathing; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 45 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Thymoglobulin, Busulfan, Fludarabine, Alloreactive NK Infusion, G-CSF, Tacrolimus, Methotrexate, Interleukin-2; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis, Fungal Infection, Allergic Bronchopulmonary Aspergillosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 8 Years to 25 Years
Enrollment: 24 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Highlands Ranch, Colorado

Conditions: Obesity, Obesity; Drug, Lifestyle, Healthy
Interventions: Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG; Behavioral · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more

Conditions: Breast Carcinoma, Colorectal Carcinoma
Interventions: Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Drug · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more

Conditions: Stress Disorder, Post Traumatic
Interventions: D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hodgkin Lymphoma, Adult
Interventions: ATLCAR.CD30, Bendamustine, Fludarabine; Genetic · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: VX-509; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Upland, California • Fort Lauderdale, Florida • Venice, Florida + 15 more

Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
Interventions: CC-486, Carboplatin, ABI-007; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more

Search by objective public record fields.

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

CBD Knee Osteoarthritis Study

Community Partners in Care is a Research Project Funded by the National Institutes of Health

Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone

The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta

Improving Communication for Primary Care Patients

Pedal Movement - Implementing Cycling as a Mobility Option

Treatment for CI-DME in Eyes With Very Good VA Study

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

Enteric Neural Precursor Cells (ENPC) in the Human Gut

Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Activate For Life: mHealth Intervention To Address Pain And Fatigue In Low-income Older Adults Aging In Place

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Immune Profiles in CF Fungal Infection

Long-term Effectiveness of the Antiobesity Medication Phentermine

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

Compassionate Use Re-Infusion of ATLCAR.CD30

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors